Circle RNA Regulation of Lung Cancer Metastasis
Circle RNA对肺癌转移的调控
基本信息
- 批准号:10637900
- 负责人:
- 金额:$ 32.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-04 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAlternative SplicingAntisense OligonucleotidesArchitectureBioinformaticsBiologicalCancer EtiologyCancer PatientCerebellar Degeneration Related 1 AntisenseCerebellar degenerationCessation of lifeChemicalsClinicalCoat Protein Complex ICodeComplexCouplesCuesCytoskeletonDataDependenceElectron MicroscopyElementsEpitheliumGenetic EpistasisGenetic TranscriptionGolgi ApparatusImmunohistochemistryInterruptionKnock-outLigandsLightLung AdenocarcinomaMalignant NeoplasmsMalignant neoplasm of lungMapsMediatingMesenchymalMessenger RNAMethodsMicroscopyModelingMolecular ProfilingMutateNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNucleotidesOligonucleotidesOutcomePathway interactionsPatientsPhenotypePlayPrimary NeoplasmProteinsRNARNA StabilityRegulationResolutionRoleSamplingSiteSquamous Cell Lung CarcinomaStructureSurvival RateSystemic TherapyThe Cancer Genome AtlasTherapeuticUntranslated RNAVesicleanticancer researchchemotherapyexperimental studygenetic approachhuman diseaseimprovedinsightmigrationmouse modelnovel therapeuticsoverexpressionprogramsprotein transportspatial relationshipstemtargeted treatmenttraffickingtumortumorigenicvesicle transport
项目摘要
Lung cancer is the leading cause of cancer-related deaths in the U.S., accounting for about 132,000 deaths per
year. While targeted therapies of lung adenocarcinoma have improved overall survival, similar advances in lung
squamous carcinoma (LUSC) have been stagnant. Extensive molecular profiling through the Cancer Genome
Atlas (TCGA) effort revealed that LUSC tumors are highly idiosyncratic and rarely driven by solitary actionable
pathways. Also, metastasis, rather than primary tumors, is responsible for the majority of cancer-related deaths.
However, the mechanistic underpinnings of how LUSC spreads are very poorly understood. In this proposal, we
will investigate the roles of a circle RNA (circRNA), CDR1as, on its regulation of LUSC metastasis. To investigate
the regulatory role of CDR1as on LUSC metastasis, we have recently developed sophisticated LUSC models
that metastasize to sites common to human disease. By integrating clinical LUSC TCGA data with our mouse
models, we have identified CDR1as as a key driver of LUSC metastasis. We have found that CDR1as plays a
key role in stabilizing the coding mRNA transcript for cerebellar degeneration-related protein 1 (CDR1). We found
that CDR1as and CDR1 are each necessary for LUSC metastasis, and CDR1 over-expression alone is sufficient
to promote LUSC metastasis. We found CDR1 interacts with several specific Golgi trafficking proteins, and CDR1
expression corresponds with poor LUSC survival and tightly couples with an epithelial-mesenchymal transition
(EMT) program. Additionally, we have found key structural elements of CDR1as that promote its RNA stability
and expression levels. Taken together, key questions arise, such as: 1) How does CDR1 trafficking in the Golgi
vesicles promote migration and metastasis? 2) Can oligo-mediated targeting of CDR1as block LUSC metastasis
and prolong survival? The objectives of this proposal are to define how CDR1 promotes LUSC metastasis
through Golgi trafficking. We will also determine the biologic and therapeutic implications of interrupting structural
elements of CDR1as.
肺癌是美国与癌症相关死亡的主要原因,约占132,000人死亡
年。虽然针对肺腺癌的靶向疗法提高了总体生存率,但肺部的进展相似
鳞状癌(LUSC)停滞不前。通过癌症基因组进行广泛的分子分析
Atlas(TCGA)的努力表明,LUSC肿瘤是高度特质的,很少受到孤立驱动的驱动
途径。同样,转移而不是原发性肿瘤是造成大多数与癌症相关的死亡的原因。
但是,LUSC传播方式的机械基础知之甚少。在这个建议中,我们
将研究圆圈RNA(circRNA),CDR1AS对LUSC转移的调节的作用。调查
CDR1AS在LUSC转移中的调节作用,我们最近开发了复杂的LUSC模型
转移到人类疾病常见的部位。通过将临床LUSC TCGA数据与我们的鼠标集成
模型,我们将CDR1AS确定为LUSC转移的关键驱动力。我们发现CDR1A扮演
在稳定小脑变性相关蛋白1(CDR1)的编码mRNA转录本方面的关键作用。我们发现
CDR1A和CDR1对于LUSC转移都是必需的,仅CDR1过表达就足够了
促进LUSC转移。我们发现CDR1与几种特定的高尔基运输蛋白相互作用,而CDR1
表达与LUSC生存不良,并与上皮间质转变紧密伴侣
(EMT)程序。此外,我们发现CDR1A的关键结构元素促进其RNA稳定性
和表达水平。综上
囊泡促进迁移和转移? 2)寡核介导的CDR1AS块块lusc转移的靶向
延长生存?该提案的目标是定义CDR1如何促进LUSC转移
通过高尔基人贩运。我们还将确定中断结构的生物学和治疗意义
CDR1A的元素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chad V Pecot其他文献
Chad V Pecot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chad V Pecot', 18)}}的其他基金
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
配体导向的 KRAS G12V 突变特异性治疗
- 批准号:
10757070 - 财政年份:2023
- 资助金额:
$ 32.9万 - 项目类别:
Development of EFTX-001 to target KRAS mutations in cancer
开发 EFTX-001 以靶向癌症中的 KRAS 突变
- 批准号:
9906510 - 财政年份:2020
- 资助金额:
$ 32.9万 - 项目类别:
相似国自然基金
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
- 批准号:82372743
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
MEK/ERK通路对Bim选择性剪接的调节及其在胃癌细胞对化疗敏感性中作用
- 批准号:81071809
- 批准年份:2010
- 资助金额:33.0 万元
- 项目类别:面上项目
Dyrk1A调控CaMKⅡδ的可变剪接及其在心脏重构过程中的作用
- 批准号:30971223
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
相似海外基金
Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
开发反义寡核苷酸来调节γ纤维蛋白原水平
- 批准号:
10759950 - 财政年份:2023
- 资助金额:
$ 32.9万 - 项目类别:
Mapping proximal and distal splicing-regulatory elements
绘制近端和远端剪接调控元件
- 批准号:
10658516 - 财政年份:2023
- 资助金额:
$ 32.9万 - 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 32.9万 - 项目类别:
Identifying the function of alternatively spliced TDP43 isoforms and contribution to disease
确定选择性剪接 TDP43 亚型的功能及其对疾病的影响
- 批准号:
10748166 - 财政年份:2023
- 资助金额:
$ 32.9万 - 项目类别:
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
IND 促进 E1v1.11 的非临床开发,E1v1.11 是一种用于治疗脊髓性肌萎缩症的吗啉代反义寡核苷酸。
- 批准号:
10569744 - 财政年份:2023
- 资助金额:
$ 32.9万 - 项目类别: